At Cortado Ventures, we back entrepreneurs that are inventing the future, and we are thrilled about our investment in Moat Biotechnology. Moat’s technology is based on a next-generation adenovirus platform from the Mayo Clinic. Our General Partner Mike Moradi articulates our commitment to Moat Biotechnology, the first western company to demonstrate a successful inhaled COVID booster in a human clinical trial. Read More.
Recent Posts
- Cortado Ventures Strengthens Vision to Advance Market Leadership in 2025
- Applying Systems-Thinking to Maximize Community Impact with Lynn McBee
- College is Perfect Time to Found Your first Startup with Trevor Gicheru
- Overcoming Addiction to Achieve Athletic and Podcasting Fame with Rich Roll
- Women Founders Seeding and Expanding the Biotech Industry in OKC!